Terapie
In rosso le Review, in verde gli RCT.
Coronavirus Drug and Treatment Tracker (in continuo aggiornamento)
Qui le news su Farmaci & COVID-19 a cura di Farmacovigilanza.eu, il portale del Centro Regionale di Farmacovigilanza della Regione Veneto, a cui contribuisce anche il Reference Centre for Education and Communication within the WHO International Programme for Drug Monitoring, con sede a Verona.
-
Clorochina e idrossiclorochina
- > AIFA, update 22 dicembre 2020 - aggiornamento | “ Idrossiclorochina nei pazienti adulti con COVID-19”
- > EMA, 27 novembre 2020 | "Update to information on psychiatric disorders for chloroquine and hydroxychloroquine"
- > AIFA, 25 novembre 2020 – aggiornamento | “Idrossiclorochina nei pazienti adulti con Covid-19"
- > New England Journal of Medicine , 24 novembre 2020 | “A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19”
- > JAMA, 9 novembre 2020 | “Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19- A Randomized Clinical Trial”
-
ARCHIVIO
-
Remdesivir
- > Annals of Internal Medicine, 1 marzo 2022 | “Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points”
- > New England Journal of Medicine , 21 dicembre 2021 | “Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients”
- > The Lancet Infectious Diseases, 14 settembre 2021 | “Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial”
- > New England Journal of Medicine, 4 marzo 2021 | “Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19”
- > Annals of Internal Medicine, 9 febbraio 2021 | “Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians”
-
ARCHIVIO
-
Interferone
- > The Lancet Respiratory Medicine , 5 febbraio 2021 | “Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial”
- > The Lancet Respiratory Medicine , 12 novembre 2020 | “Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
- > Associazione Alessandro Liberati - Network Italiano Cochrane, 8 maggio 2020 | Interferone e ribavirina in aggiunta a lopinavir + ritonavir in pazienti COVID con malattia lieve o moderata
- > The Lancet, 8 maggio 2020 | “Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial”
- > Editoriale di commento, 8 maggio 2020 | ”Interferon beta-1b and COVID-19”
-
Lopinavir/Ritonavir
- > The Lancet, 5 ottobre 2020 | “Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial”
- > New England Journal of Medicine, 5 maggio 2020 | “A Trial of Lopinavir–Ritonavir in Covid-19”
- > Associazione Alessandro Liberati - Network Italiano Cochrane, 18 marzo maggio 2020 | Lopinavir-ritonavir in pazienti ospedalizzati con Covid-19 avanzata: i risultati del primo RCT
- > New England Journal of Medicine, 18 March 2020 | “Uno studio randomizzato sull’efficacia del trattamento con Lopinavir-Ritonavir (I Articolo)”
-
Eparine a basso peso molecolare
- > JAMA Internal Medicine, 7 ottobre 2021 | “Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19”
- > JAMA Internal Medicine, editoriale 7 ottobre 2021 | “Anticoagulant Therapy in Patients Hospitalized With COVID-19”
- > New England Journal of Medicine, 4 agosto 2021 | “Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19”
- > New England Journal of Medicine, 4 agosto 2021 | “Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19”
- > New England Journal of Medicine, editoriale 4 agosto 2021 | “Surviving Covid-19 with Heparin?”
-
ARCHIVIO
-
Anticorpi monoclonali
- - New England Journal of Medicine, 20 aprile 2022 | “Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19”
- - JAMA, 14 marzo 2022 | “Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19”
- > New England Journal of Medicine, 9 marzo 2022 | “Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2”
- > New England Journal of Medicine , 9 marzo 2022 | “Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use”
- > JAMA, 14 gennaio 2022 | “Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection”
-
ARCHIVIO
-
Plasma da pazienti guariti
- > New England Journal of Medicine, 30 marzo 2022 | “Early Outpatient Treatment for Covid-19 with Convalescent Plasma”
- > The Lancet , 27 gennaio 2022 | “Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial”
- > Science, 21 dicembre 2021 | “Convalescent plasma shows renewed promise for COVID-19 in outpatient trial”
- > JAMA, 4 ottobre 2021 | “Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19A Randomized Clinical Trial”
- > New England Journal of Medicine, 18 agosto 2021 | “Early Convalescent Plasma for High-Risk Outpatients with Covid-19”
-
ARCHIVIO
-
Azitromicina
- >The Lancet , 2 febbraio 2021 | “Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial”
- > MJ Open, 12 maggio 2020 | “Should azithromycin be used to treat COVID-19? A rapid review”
- > AIFA, update 5 maggio 2020 | “Azitromicina nella terapia dei pazienti adulti con COVID-19”
-
Inibitori interleuchina-6 (Tocilizumab/Sarilumab)
- > The Lancet Respiratory Medicine , 29 ottobre 2021 | “Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial”
- > The Lancet Respiratory Medicine , editoriale 29 ottobre 2021 | “The course of action for effective anti-cytokine treatment in COVID-19”
- > JAMA, 6 luglio 2021 | “Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19A Meta-analysis”
- > JAMA, 6 luglio editoriale | “IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19 - Who, When, and How?”
- > JAMA Internal Medicine, 24 maggio 2021 | “Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial”
-
ARCHIVIO
-
Anakinra
- > Nature Medicine, 3 settembre 2021 | “Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial”
- > The Lancet Respiratory Disease, 22 gennaio 2021 | “Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial”
- > NICE, 21 maggio 2020 | “COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis”
- > The Lancet Rheumatology, 29 maggio 2020 | “Anakinra for severe forms of COVID-19: a cohort study”
-
Corticosteroidi
- > JAMA, 21 ottobre 2021 | “Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe HypoxemiaThe COVID STEROID 2 Randomized Trial”
- > JAMA, 21 ottobre editoriale | >strong>“Glucocorticoid Dose in COVID-19Lessons for Clinical Trials During a Pandemic”
- - The Lancet, 10 agosto 2021 | “Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial”
- - The Lancet, 10 agosto 2021 editoriale | “The use of inhaled corticosteroids in early-stage COVID- 19”
- > The Lancet Respiratory Medicine, 9 aprile 2021 | “Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial”
-
ARCHIVIO